palliative benefits of the multimodality approach in the re-treatment of recurrent malignant glioma: two case reports

Clicks: 422
ID: 181965
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #12 of 41 articles by views in Öneri

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Two young male patients treated seven and four years back, for malignant glioma, returned with recurrence at the same site, with a World Health Organization (WHO) Performance Score of four and two. Both underwent resurgery and received postoperative reirradiation of 5040 cGy in 28 fractions and concurrent Temozolomide 75 mg/m 2 body surface area (BSA) daily, and one patient received additional adjuvant Temozolomide 250 mg (150 mg/m 2 BSA). Both patients tolerated the treatment well with 16 and 14 months follow-up from the time of recurrence. They were symptom-free, with normal physical function and good mental state, and resumed their respective jobs.
Reference Key
arulponni2009indianpalliative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;T R Arulponni;M G Janaki;S Nirmala
Journal Öneri
Year 2009
DOI
10.4103/0973-1075.58464
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.